Share

September 22, 2009; 73 (12) Articles

Randomized, controlled trial of telcagepant for the acute treatment of migraine

K. M. Connor, R. E. Shapiro, H. -C. Diener, S. Lucas, J. Kost, X. Fan, K. Fei, C. Assaid, C. Lines, T. W. Ho
First published September 21, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181b87942
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1515

Share

Article Information

vol. 73 no. 12 970-977
DOI: 
https://doi.org/10.1212/WNL.0b013e3181b87942
PubMed: 
19770473
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published September 21, 2009.
Copyright & Usage: 
© 2009

Author Disclosures

    1. K. M. Connor, MD,
    2. R. E. Shapiro, MD, PhD,
    3. H. -C. Diener, MD,
    4. S. Lucas, MD, PhD,
    5. J. Kost, PhD,
    6. X. Fan, PhD,
    7. K. Fei, MD,
    8. C. Assaid, PhD,
    9. C. Lines, PhD and
    10. T. W. Ho, MD
  1. K. M. Connor, MD,
  2. R. E. Shapiro, MD, PhD,
  3. H. -C. Diener, MD,
  4. S. Lucas, MD, PhD,
  5. J. Kost, PhD,
  6. X. Fan, PhD,
  7. K. Fei, MD,
  8. C. Assaid, PhD,
  9. C. Lines, PhD and
  10. T. W. Ho, MD
  1. From the Merck Research Laboratories (K.M.C., J.K., X.F., K.F., C.A., C.L., T.W.H.), North Wales, PA; University of Vermont College of Medicine (R.E.S.), Burlington; University of Duisburg-Essen (H.-C.D.), Germany; and University of Washington Medical Center (S.L.), Seattle.
  1. Address correspondence and reprint requests to Dr. Tony Ho, Merck Research Laboratories, UG 4C-18, PO Box 1000, North Wales, PA 19454-1099 tony_ho{at}merck.com
View Full Text

Article usage

Article usage: September 2009 to December 2020

AbstractFullPdfSource
Sep 200936186140Highwire
Oct 200916265114Highwire
Nov 20091114973Highwire
Dec 2009612126Highwire
Jan 2010523226Highwire
Feb 2010513526Highwire
Mar 2010672024Highwire
Apr 2010581421Highwire
May 2010511318Highwire
Jun 2010361315Highwire
Jul 2010601214Highwire
Aug 201034914Highwire
Sep 201049710Highwire
Oct 20104496Highwire
Nov 20101101Highwire
Dec 20103043Highwire
Jan 20114859Highwire
Feb 201158610Highwire
Mar 201153914Highwire
Apr 20113203Highwire
May 20114026Highwire
Jun 20112731Highwire
Jul 20113644Highwire
Aug 20111834Highwire
Sep 20113153Highwire
Oct 20112810Highwire
Nov 20113341Highwire
Dec 20112813Highwire
Jan 20121120Highwire
Feb 20121800Highwire
Mar 20122712Highwire
Apr 20121410Highwire
May 20124053Highwire
Jun 20123311Highwire
Jul 20122200Highwire
Aug 2012812Highwire
Sep 20121511Highwire
Oct 20121437Highwire
Nov 20122400Highwire
Dec 20121802Highwire
Jan 20132121Highwire
Feb 20133011Highwire
Mar 20132200Highwire
Apr 20133152Highwire
May 20131413Highwire
Jun 20131601Highwire
Jul 20131402Highwire
Aug 20131000Highwire
Sep 20131000Highwire
Oct 20132642Highwire
Nov 20131610Highwire
Dec 20131112Highwire
Jan 20141100Highwire
Jan 201402321pmc
Feb 20141123Highwire
Mar 20142304Highwire
Apr 20142612Highwire
May 2014910Highwire
Jun 20141811Highwire
Jul 20143201Highwire
Aug 20141710Highwire
Sep 20141522Highwire
Oct 20142101Highwire
Nov 20143005Highwire
Dec 20141821Highwire
Jan 20152211Highwire
Jan 201501418pmc
Feb 20151500Highwire
Feb 201501913pmc
Mar 20153100Highwire
Mar 201501416pmc
Apr 20151314Highwire
Apr 201502316pmc
May 2015200Highwire
May 201501819pmc
Jun 20152212Highwire
Jun 201501915pmc
Jul 20152123Highwire
Jul 201502317pmc
Aug 2015811Highwire
Aug 201502024pmc
Sep 2015800Highwire
Sep 201502918pmc
Oct 2015700Highwire
Oct 201502218pmc
Nov 20152011Highwire
Nov 201503225pmc
Dec 20151400Highwire
Dec 201503220pmc
Jan 20161621Highwire
Jan 201602728pmc
Feb 20161701Highwire
Feb 201603515pmc
Mar 20162223Highwire
Mar 201605225pmc
Apr 20161320Highwire
Apr 201606119pmc
May 2016900Highwire
May 201601713pmc
Jun 20161000Highwire
Jun 201601414pmc
Jul 20161521Highwire
Jul 201602113pmc
Aug 20161211Highwire
Aug 201602116pmc
Sep 20162401Highwire
Sep 201602221pmc
Oct 20161511Highwire
Oct 20160216pmc
Nov 20161400Highwire
Nov 201604312pmc
Dec 20161811Highwire
Dec 20160124pmc
Jan 20173300Highwire
Jan 201704011pmc
Feb 20172111Highwire
Feb 201702610pmc
Mar 20173100Highwire
Mar 20170328pmc
Apr 20172100Highwire
Apr 201761721pmc
May 20172200Highwire
May 2017202929pmc
Jun 2017500Highwire
Jun 2017103030pmc
Jul 2017800Highwire
Jul 201752226pmc
Aug 20171933Highwire
Aug 2017123035pmc
Sep 20171011Highwire
Sep 201792326pmc
Oct 20171300Highwire
Oct 201772224pmc
Nov 20172221Highwire
Nov 201784870pmc
Dec 20171600Highwire
Jan 20182333Highwire
Feb 20182420Highwire
Mar 20182321Highwire
Apr 20182621Highwire
Apr 201822632pmc
May 20182976Highwire
Jun 20181500Highwire
Jun 201833241pmc
Jul 20181011Highwire
Aug 20181500Highwire
Aug 201871419pmc
Sep 20181712Highwire
Oct 20182411Highwire
Nov 20182202Highwire
Dec 20182811Highwire
Jan 20192900Highwire
Feb 2019800Highwire
Mar 20192002Highwire
Apr 20191400Highwire
May 20191421Highwire
Jun 20191300Highwire
Jul 20192713Highwire
Aug 20191400Highwire
Sep 2019800Highwire
Oct 20194634Highwire
Nov 20192510Highwire
Dec 20191920Highwire
Jan 20203131Highwire
Feb 20203343Highwire
Mar 20201611Highwire
Apr 20201301Highwire
May 20201900Highwire
Jun 20201340Highwire
Jul 2020812Highwire
Aug 20201000Highwire
Sep 20202510Highwire
Oct 20202011Highwire
Nov 20201921Highwire
Dec 20202600Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

  • Randomized, controlled trial of telcagepant for the acute treatment of migraine
    • Rachel Nardin, Cambridge Health Alliance, 1493 Cambridge St. Macht 420, Cambridge MA 02139
    Submitted November 20, 2009
  • Reply from the authors
    • Tony W. Ho, Merck Research Laboratories, UG 4C-18, PO Box 1000, North Wales, PA 19454-1099
    • Kathryn M. Connor, Robert E. Shapiro, Hans-Christoph Diener, Sylvia Lucas, James Kost, Xiaoyin Fan, Kaiyin Fei, Christopher Assaid, Christopher Lines
    Submitted November 20, 2009
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me